Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$51.54 USD
-3.78 (-6.83%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $51.60 +0.06 (0.12%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VKTX 51.54 -3.78(-6.83%)
Will VKTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
Other News for VKTX
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Viking Therapeutics initiated with bullish view at Morgan Stanley, here's why
Buy Recommendation for Viking Therapeutics on Strong Pipeline Potential in Metabolic Diseases
BUZZ Investing: U.S. Stocks Rally As Nvidia Climbs Higher